Depressive Disorder News and Research

RSS

Individuals taking antidepressants may experience personality change, says new report

Individuals taking a medication to treat depression may experience changes in their personality separate from the alleviation of depressive symptoms, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

Rush University Medical Center opens TMS Clinic to offer non-drug treatment for depression

Rush University Medical Center has opened the Transcranial Magnetic Stimulation (TMS) Clinic to offer patients suffering from major depression a safe, effective, non-drug treatment. TMS therapy is the first FDA-approved, non-invasive antidepressant device-based treatment clinically proven for treatment of depression.

6 Nov 2009

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

29 Oct 2009

New clinical uses for old hypertension drug leads to several patents

University of South Florida neuroscientist R. Douglas Shytle's discovery of successful new clinical uses for mecamylamine, a drug once used to treat hypertension, has led to several issued patents on mecamylamine and related compounds. Earlier this month, Shytle, associate professor and research scientist at the USF Center of Excellence for Aging and Brain Repair and the USF Silver Child Development Center, received the university's 2009 "Excellence in Innovation" award.

28 Oct 2009

New therapy for decreasing anxiety and improving psychological well-being in children

A group of investigators of the University of Bologna suggest a new way of approaching emotional disturbances in children by improving their psychological well-being. The study is published in the current issue of Psychotherapy and Psychosomatics.

27 Oct 2009

Study explores the link between child sexual abuse and inability to express emotions in adulthood

An investigation published in the current issue of Psychotherapy and Psychosomatics explores the link between child sexual abuse and inability to express emotions in adulthood.

27 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

The Patient Recruiting Agency begins patient recruitment for major depressive disorder

The Patient Recruiting AgencyTM announces that on October 20th 2009 it will begin recruiting patients with major depressive disorder for a series of medical research studies.

21 Oct 2009

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.

20 Oct 2009

Bioscience Research offers mental health care at no cost

Psychiatrists at Bioscience Research, LLC, understand the mental health burden that can accompany unemployment and the day-to-day stress of looking for a new job or worrying about losing an existing job.

22 Sep 2009

New report explores the management of pregnancy and depression

A new report from the American Psychiatric Association (APA) and the American College of Obstetricians and Gynecologists, which is published by Elsevier in the September-October 2009 issue of General Hospital Psychiatry (http://journals.elsevierhealth.com/periodicals/ghp/home), explores the management of pregnancy and depression.

21 Sep 2009

Depression increases disease progression and mortality in cancer patients

Depression can affect a cancer patient's likelihood of survival. That is the finding of an analysis published in the November 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society. The results highlight the need for systematic screening of psychological distress and subsequent treatments.

14 Sep 2009

Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems

Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that two companion articles highlighting results from the BRITE-MD (Biomarkers for Rapid Identification of Treatment Effectiveness trial in Major Depression) were published in the September issue of the journal Psychiatry Research.

11 Sep 2009

Biomarkers for rapid identification of treatment effectiveness in major depression

Now, based on the final results of a nationwide study led by UCLA, clinicians may be able to accurately predict within a week whether a particular drug will be effective by using a non-invasive test that takes less than 15 minutes to administer. The test will allow physicians to quickly switch patients to a more effective treatment, if necessary.